An unexpected laboratory finding has given researchers a new way to think about preventing the flu: stop the virus before it gets inside human cells.
While studying how influenza replicates, scientists discovered that different flu strains do not necessarily use the same method to enter cells. The finding could help guide future efforts to develop preventive medications that target the specific molecules each strain depends on.
The discovery, reported by SWNS and published in The Journal of Virology, centers on two major influenza A strains: H1N1 and H3N2.
The Accidental Breakthrough
The study did not begin as a search for a new flu prevention strategy.
Researchers originally set out to understand how viral RNA segments move inside infected cells to help create new virus particles. During that work, they came across something unexpected: a cellular pathway that appeared to stop one flu strain from entering lung cells.
That pathway involved a human protein called Rab11B.
When researchers depleted Rab11B, H3N2 viruses failed to enter human lung cells. H1N1 viruses, however, were unaffected.
That difference was the key discovery. It suggested that these two flu strains depend on different host-cell factors during the earliest stage of infection.
Why Rab11B Matters
The Rab11B finding challenged a long-standing assumption in flu research.
Scientists had previously thought that flu viruses generally entered cells in the same way. But the study showed that H3N2 appeared to need Rab11B for entry, while H1N1 did not.
Using reverse genetics, the research team mapped the defect and identified a new H3N2-specific role for Rab11B during viral entry.
That matters because stopping a virus from entering cells could stop it from spreading through the body. As principal investigator Dr. Emily Bruce of the University of Vermont’s Larner College of Medicine explained, illness does not come from a virus sitting in one cell. It comes when the virus replicates and spreads into many more cells.
The study focused on H1N1 and H3N2 viruses taken from the nasal passages of patients who tested positive in 2022.
Both strains can cause seasonal flu illness, and both are among the most common influenza A viruses. But current flu tests do not distinguish between the two, and clinical treatment remains the same for both.
The new research suggests that this one-size-fits-all approach may not reflect what is happening at the cellular level.
If different flu strains rely on different proteins to enter cells, researchers may eventually be able to design treatments that block one strain more precisely than another.
The Pirate Analogy
Bruce described the discovery with a simple comparison.
“Viruses are like pirates from different countries hijacking someone’s ship,” she said in the SWNS report.
Her point was that different viruses may use different tactics to get inside a cell. In this study, H1N1 and H3N2 did not appear to use the same host protein in the same way.
“We had previously thought that all flu viruses used the same way to get into a cell, but we discovered that this is not true,” Bruce said.
She added that H1N1 and H3N2 need different proteins to enter cells, and if researchers remove the right protein, a specific virus may be unable to get in.
The finding matters because flu prevention has long depended heavily on vaccines and antiviral medications.
Those tools remain important, but Bruce said there is still a serious need for better medications that can stop influenza from spreading from cell to cell.
The Rab11B discovery offers a potential new direction: target the human-cell pathway that a specific flu strain needs in order to enter.
That approach could lead to more tailored flu prevention strategies in the future. Instead of treating H1N1 and H3N2 as though they behave the same, researchers may be able to develop methods that respond to the distinct biology of each strain.
The Limits of the Study
The research is still early.
The study was conducted using isolated cells, not a live, complex human respiratory system. That means scientists do not yet know whether blocking Rab11B would be safe or effective in people.
Researchers also still need to determine whether Rab11B dependence is a fundamental feature of H3N2, or whether it is limited to currently circulating flu strains.
Those questions matter because a discovery that works in a lab dish may not always translate directly into a safe treatment for patients.
The accidental flu discovery offers a promising new clue in the fight against influenza.
By showing that H3N2 and H1N1 may enter human cells through different pathways, researchers have opened the door to more targeted ways of preventing infection. The Rab11B finding does not create an immediate new treatment, but it gives scientists a clearer path to explore.
For now, the breakthrough is an early-stage discovery. But if future research confirms that specific flu strains can be blocked by targeting the proteins they rely on, the way doctors prevent and treat influenza could eventually become far more precise.
